Evox Therapeutics Ltd logo

Evox Therapeutics Ltd

Evox is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles, exosomes to develop an entirely novel class of biotherapeutics.

Evox was founded by Prof. Matthew Wood of Oxford University, Asst. Prof. Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property on exosome research carried out in these two world-leading labs.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.evoxtherapeutics.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Oxford Science ParkMedawar Centre2nd Floor East Building Robert Robinson Avenue, OX4 4HG
Oxford
United Kingdom
Email
enquiries@evoxtherapeutics.com
Contact Number
+44 1865 819140

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/evox-therapeutics-ltd” connections=”true” suffix=””]

Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. The exosomes technology developed could provide a way to clear the _blood-brain barrierÓ which prevents 98% of current drugs from reaching the brain, providing treatments to Alzheimers and many cancers.

In Dec 2017, Evox Therapeutics entered into a research collaboration with Boehringer Ingelheim to investigate exosome-mediated delivery of RNAs to target specific disease areas. The financial considerations remain undisclosed. Upon completion of studies,Boehringer will have option to negotiate agreement to further develop RNA drug candidates using Evoxs technology.

In May 2016, EvOx Therapeutics raised £10m in Series A round from Oxford Sciences Innovation, supported by Invesco, Lansdowne Partners and Woodford Investment Management.